GENEREACH BIOTECHNOLOGY CORP. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 31.95 TWD | +0.47% |
|
+5.10% | -19.01% |
| Sales 2022 | 750M 23.02M 1.84B | Sales 2023 | 225M 6.92M 553M | Capitalization | 2.27B 69.58M 5.56B |
|---|---|---|---|---|---|
| Net income 2022 | 221M 6.78M 543M | Net income 2023 | -166M -5.1M -408M | EV / Sales 2022 | 3.57 x |
| Net cash position 2022 | 359M 11.01M 881M | Net cash position 2023 | 254M 7.8M 624M | EV / Sales 2023 | 8.93 x |
| P/E ratio 2022 |
14.1
x | P/E ratio 2023 |
-13.6
x | Employees | - |
| Yield 2022 |
2.27% | Yield 2023 |
-
| Free-Float | 67.66% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.47% | ||
| 1 week | +5.10% | ||
| Current month | -5.05% | ||
| 1 month | -4.63% | ||
| 3 months | -13.88% | ||
| 6 months | +1.75% | ||
| Current year | -19.01% |
1 week
30.10
32.00
1 month
29.2034.00
Current year
29.2042.80
1 year
29.2047.52
3 years
29.20137.45
5 years
26.84307.30
10 years
11.13307.30
| Managers | Title | Age | Since |
|---|---|---|---|
Hsiao-Fen Chang
CEO | Chief Executive Officer | - | 31/08/10 |
Cheng-Chung Liu
FOU | Founder | - | 11/11/04 |
Hsiu Ying Chang
DFI | Director of Finance/CFO | - | 09/08/15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Cheng-Chung Liu
FOU | Founder | - | 11/11/04 |
Hsiao-Fen Chang
CEO | Chief Executive Officer | - | 31/08/10 |
Cheng Su
BRD | Director/Board Member | - | 31/12/04 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 31.95 | +0.47% | 158,699 |
| 25/04/24 | 31.8 | +1.76% | 146,124 |
| 24/04/24 | 31.25 | +1.96% | 136,674 |
| 23/04/24 | 30.65 | +0.33% | 64,575 |
| 22/04/24 | 30.55 | +0.49% | 132,598 |
End-of-day quote Taipei Exchange, April 25, 2024
More quotes
GeneReach Biotechnology Corp. is principally engaged in the manufacture and distribution of animal testing equipment and testing agents. The Company mainly operates through Taiwan segment. The Company provides shrimp virus testing agents, on-site detection systems for fish and shrimp, mini centrifugal machines, pet disease testing agents and other testing equipment.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| -19.01% | 56.28M | |
| -22.83% | 1.45B |
- Stock Market
- Equities
- 4171 Stock
